Maslow M J, Simberkoff M S, Rahal J J
J Antimicrob Chemother. 1985 Aug;16(2):227-34. doi: 10.1093/jac/16.2.227.
The synergistic activity of cefotaxime and amikacin against 21 highly resistant Pseudomonas aeruginosa and Serratia marcescens isolates was evaluated in-vitro by the checkerboard tube dilution method and in-vivo in five patients with serious infections caused by these organisms. All isolates were resistant to gentamicin, tobramycin, amikacin, and cefotaxime. Synergy was observed in 90% of isolates and occurred when the MIC of amikacin was less than 256 mg/l and of cefotaxime less than 1024 mg/l. A clinical response occurred in 100% and bacteriological cure in 80% of patients. Our results demonstrate a high degree of synergism between amikacin and cefotaxime in-vitro and clinical efficacy in the treatment of infections due to multiply-resistant Pseudomonas and Serratia species.
采用棋盘式试管稀释法体外评估了头孢噻肟和阿米卡星对21株高度耐药铜绿假单胞菌和粘质沙雷氏菌分离株的协同活性，并在5例由这些微生物引起严重感染的患者体内进行了评估。所有分离株均对庆大霉素、妥布霉素、阿米卡星和头孢噻肟耐药。在90%的分离株中观察到协同作用，当阿米卡星的最低抑菌浓度（MIC）小于256mg/L且头孢噻肟的MIC小于1024mg/L时出现协同作用。100%的患者出现临床反应，80%的患者实现细菌学治愈。我们的结果表明，阿米卡星和头孢噻肟在体外具有高度协同作用，在治疗多重耐药铜绿假单胞菌和沙雷氏菌属引起的感染方面具有临床疗效。
